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1-year follow-up of neurofeedback treatment in
adolescents with attention-deficit hyperactivity
disorder: randomised controlled trial
Marleen Bink, Ilja L. Bongers, Arne Popma, Tieme W.P. Janssen and Chijs van Nieuwenhuizen
Background
Estimates of the effectiveness of neurofeedback as a
treatment for attention-deficit hyperactivity disorder (ADHD)
are mixed.
Aims
To investigate the long-term additional effects of
neurofeedback (NFB) compared with treatment as usual (TAU)
for adolescents with ADHD.
Method
Using a multicentre parallel-randomised controlled trial
design, 60 adolescents with a DSM-IV-TR diagnosis of ADHD
receiving NFB+TAU (n=41) or TAU (n=19) were followed up.
Neurofeedback treatment consisted of approximately 37
sessions of theta/sensorimotor rhythm (SMR)-training on
the vertex (Cz). Outcome measures included behavioural
self-reports and neurocognitive measures. Allocation to the
conditions was unmasked.
Results
At 1-year follow-up, inattention as reported by adolescents was
decreased (range ηp
2=0.23–0.36, P<0.01) and performance on
neurocognitive tasks was faster (range ηp
2=0.20–0.67, P<0.005)
irrespective of treatment group.
Conclusions
Overall, NFB+TAU was as effective as TAU. Given the
absence of robust additional effects of neurofeedback in
the current study, results do not support the use of
theta/SMR neurofeedback as a treatment for adolescents





© The Royal College of Psychiatrists 2016. This is an open
access article distributed under the terms of the Creative
Commons Non-Commercial, No Derivatives (CC BY-NC-ND)
licence.
Attention-deficit hyperactivity disorder (ADHD) is characterised
by the re-occurring patterns of inattention and/or hyperactivity/
impulsivity symptoms that interfere with developmentally appro-
priate social, academic or occupational functioning.1 Neurodeve-
lopmental conditions such as intellectual disabilities, conduct
disorder, depression and anxiety are seen more often in youngsters
with ADHD than in youngsters without ADHD.2 In addition,
it is estimated that around a third of youngsters with autism
spectrum disorder (ASD) display ADHD comorbidity.3 Stimulant
medication and behavioural therapy are considered the treatments
of choice for ADHD. Stimulant medication is effective in reducing
ADHD symptoms in youngsters with ADHD4 and – although
possibly to a lesser extent – in youngsters with combined ADHD
and ASD.5 Although medication seems to be effective, there are
limitations as well, such as limited knowledge of long-term efficacy
and side-effects.6 Moreover, despite the persistent nature of ADHD,
the majority of adolescents with ADHD discontinue stimulant
medication before adulthood.7 Additions or alternatives to the
current treatment as usual (TAU) to reduce ADHD symptoms
further, and on a long-term basis, are therefore desirable. Neuro-
feedback has been suggested as a potentially effective intervention
for reducing ADHD8 and ASD9 symptoms.
Neurofeedback is intended to alter brain activity by providing
feedback from electroencephalogram (EEG) activity to patients;
this is expected to lead to improvements in behaviour. Overall,
youngsters with ADHD show increased theta10,11 and decreased
beta11 activity compared with typically developing youngsters.
Increased theta (4–7 Hz) is associated with lower vigilance, and
decreased beta (13–30 Hz) is associated with reduced attention.12
In addition, the sensorimotor rhythm (SMR; 12–16 Hz), measured
above the central sulcus, has been related to behavioural inhibi-
tion.13 As neurofeedback aims to reduce ADHD symptoms such as
diminished vigilance, attention and inhibition, most neurofeedback
protocols train suppression of theta activity and reinforcement of
beta (12–20 Hz) or SMR (12–15 Hz) with electrode placement on
the vertex (Cz).8,10 A complete neurofeedback intervention typi-
cally comprises 20–40 training sessions.10 The effectiveness of
neurofeedback as treatment for ADHD is still actively debated.
Estimates of the effectiveness of neurofeedback for the
treatment of ADHD range from efficacious14 to non-significant
when only probably masked studies are considered.15 It has been
suggested that a major advantage of neurofeedback over medica-
tion may be long-term effects after treatment completion. To
date there has been only one randomised controlled trial (RCT)
comparing the long-term effects of neurofeedback and stimulant
medication.16 This study demonstrated similar levels of ADHD
symptoms at 6-month follow-up for children who had received
neurofeedback (n=12) and children treated with stimulant
medication (n=11). It should be noted that at the 6-month
follow-up, 8 of the 12 children who had received neurofeedback
had started stimulant medication treatment.16 Long-term effects
of neurofeedback were found in two RCT studies: neurofeed‐
back was more effective in reducing ADHD symptoms as
reported by parents than computerised attention training up to
6 months of post-treatment as stand-alone treatment17 or add-on
treatment.18
In summary, neurofeedback is viewed as a potentially effective
treatment for ADHD symptoms. Comparative studies of short-
term effects have shown that neurofeedback training can be
as effective as stimulant medication,16,19 but evidence on the
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longterm effects of neurofeedback is limited. Since the aim of
neurofeedback is to induce enduring changes in brain regulation to
improve behaviour, we predict long-term effects as a consequence
of improved brain functioning. The aim of the current study was
therefore to investigate the value of neurofeedback as a supplement




Eligible participants were male adolescents with Dutch as their
native language, aged between 12 and 24 years, with a primary
clinical DSM-IV-TR1 diagnosis of ADHD and a full-scale total
intelligence quotient (TIQ) >80 on the Wechsler Intelligence
Scale for Children (WISC-III) or the Wechsler Adult Intelligence
Scale (WAIS-III).20,21 Adolescents diagnosed with ASD (autism,
Asperger syndrome or pervasive developmental disorder not
otherwise specified (PDD-NOS)) with confirmed clinical ADHD
symptoms sufficient for a clinical diagnosis were also included.
ADHD symptoms were verified by a Dutch semi-structured DSM-
IV-based ADHD interview for adults22 and the Mini International
Neuropsychiatric Interview (MINI).23,24 Exclusion criteria were neu‐
rological disorders, schizophrenia and other psychotic disorders.
In total 90 adolescents were randomly assigned to the treatment
groups: combined neurofeedback (NFB) and TAU (NFB+TAU
group; n=59) or TAU only (TAU group; n=31). The total drop-out
and exclusion rate after randomisation did not differ for the NFB
+TAU group (n=18, 30.5%) or the TAU group (n=12, 38.7%),
P=0.485 two-tailed Fisher’s exact test. The participant flow diagram
is presented in Fig. 1.
Medication use and comorbid disorders were allowed.
Comorbid disorders present in the final group at 1-year follow-up
were: depressive disorders (n=1), anxiety disorders (n=3),
substance-related disorders (n=3), conduct disorders (n=3), learn-
ing disorders (n=5), tic disorders (n=1) and reactive attachment
disorder (n=1). The final group characteristics are listed in Table 1.
Trial design
A multicentre parallel group study was conducted, with stratifica-
tion for age group (12–15 years, 16–20 years and 21–24 years)
and unbalanced randomisation to treatment (2 NFB+TAU: 1
TAU). Unbalanced treatment was applied to encourage study
participation by greater odds to receive neurofeedback at study
entree. The randomisation process was computer-controlled,25
using randomly varying block lengths of 3, 6, 9 and 12. An
independent administrative employee was responsible for the
assignment of participants to the treatment groups immediately
after pre-intervention assessment. The participant (and if applic-
able, his parents) was notified the same day whether he would
receive neurofeedback treatment. Allocation to the conditions was
unmasked; participants, parents, neurofeedback trainers, the out-
come assessor and clinical professionals were aware of group
allocations. Different individuals fulfilled the roles of outcome
assessor and neurofeedback trainer. All data entry was masked to
group allocation (NFB+TAU or TAU) and was checked twice by
different research assistants.
Before the study, calculation with G*power version 3.1.5.126
predicted that a total sample size of 46 would be sufficient to detect a
medium effect size (f=0.25) in a repeated measures ANOVA with
two measurements, with an alpha of 0.05 and a power of 90%. In
addition, a total sample size of 42 would be sufficient to detect a
medium effect size (f=− 0.25) in a repeated measures ANOVA with
three measurements (pre-intervention, post-intervention and
1-year follow-up), with an alpha of 0.01 and a power of 90%. We
have followed the CONSORT 2010 guidelines27 for reporting
parallel group randomised trials. This trial is registered in the




Participants received treatment as prescribed by the main therapist
in the three participating centres for child and adolescent psychiatry
(GGzE, GGzBreburg, Reinier van Arkel group). TAU was mon-
itored using an intervention questionnaire based on the Dutch
national basic programme ADHD for children and adolescents.28
Behavioural interventions included regular cognitive–behavioural
therapy, systemic therapy and/or supportive counselling for the
adolescent and/or his parent(s) (Table 1). Stimulants prescribed
included immediate release methylphenidate, sustained release
methylphenidate and dexamphetamine. One participant used
dexamphetamine at study entry and direct post-intervention but
changed to sustained release methylphenidate at 1-year follow-up.
Two participants were taking atomoxetine at study entry; one
participant had changed to sustained release methylphenidate by
the time of the 1-year follow-up, and the other participant con‐
tinued to use atomoxetine through the 1-year follow-up. Because
the clinical effects of stimulant medication and atomoxetine
are suggested to be similar, this participant was categorised as
stimulant-medicated for the purposes of analysis at 1-year follow-up.
There were no group differences (TAU v. NFB+TAU) in the
use of stimulant medication or the type of behavioural therapy
received (Table 1).
NFB+TAU
Neurofeedback training was carried out over a period of around
5 months (25 weeks), with two to three training sessions every week.
Each participant was offered a total of 40 30-minute training
sessions. The mean number of training sessions received was 38
(s.d.54.43), with a minimum of 19 sessions for the adolescents in
the NFB+TAU group at 1-year follow-up (n=41). A theta/SMR
training29 – a form of theta/beta training –was used, with thresholds
to inhibit theta/alpha frequency bands (4–7 and 8–11 Hz), reward
SMR activity (13–15 Hz) and inhibit beta/gamma (22–36 Hz)
conducted on Cz. The intervention conditions are described in
more detail elsewhere.30
Outcome measures
Outcome measures included three behavioural self-reports as
primary outcome measures and four neurocognitive secondary
outcome measures.
Primary behavioural outcome measures
Primary outcome measures included the following.
. The MINI:23,24 ADHD subscales for children and adolescents
covering inattention and hyperactivity/impulsivity symptoms
over the last 6 months (scale range: 0–9).
. The ADHD rating scale, a DSM-IV-based self-report for
adults31,32 (adapted from DuPaul et al33), with subscales for in‐
attention and hyperactivity/impulsivity (scale range: 0–9).34,35
. The Youth Self Report (YSR):36 the attention problems
subscale, the externalising problems scale and total problems
scale were used. Participants aged over 18 years also
completed the YSR, as most of them were still attending
school and living with their parents.
Bink et al
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Secondary neurocognitive outcome measures
Secondary outcome measures included the following.
. The D2 Attention and Concentration Test37 raw scores for
total processed items and total correctly processed items.
. The digit span backwards (DSB):30 total score (number of
rows recalled correctly) and the maximum correctly recalled
row length.
. The Stroop Color-Word Test38,39 for total execution time of
the colour-word card and interference time.
Assessed for eligibility (n=106)
Excluded (n=16)
Analysed (n=45)
Excluded from analysis (n=2)
Excluded: borderline disorder (n=1) 
Excluded: expression of psychotic
symptoms (n=1)  
Allocated to neurofeedback+treatment as 
usual (n=59)
Lost to follow-up (n=5)
Discontinued intervention due to 
motivational and/or organisational
reasons (n=5)




































Applied for eligibility (n=141) 
Declined to participate (n=35)
Analysed 
Completers (n=41)
Lost to follow-up due to motivational
and/or organisational reasons (n=4) 
Intention to treat (n=56) 
As randomised minus the excluded 
Analysed
Completers (n=19)
Lost to follow-up due to motivational
and/or organisational reasons (n=7)
















Not meeting inclusion criteria (n=8)•
Declined to participate (n=8)•
Lost to follow-up (n=12)
1-year post-intervention
Discontinued intervention due to
motivational and/or organisational
reasons (n=9)  
•
Transferred to other region for clinical 
admission (n=2)
•
Excluded: expression of bipolar disorder







Fig. 1 Participant flow diagram.
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. The Tower of London (TOL) test:40 for the raw total correct,
total moves, initiation time, execution time and total time were
calculated.
Procedure
Before the start of the study, approval was obtained from
the Medical Ethics Committee for Mental Health Institutions in
The Netherlands (Ref. no: NL 24776.097.08 CCMO). The study
took place in three centres for child and adolescent psychiatry
(GGzE, GGzBreburg, Reinier van Arkel group) in the south of
The Netherlands. After the study was explained (verbally and in
writing), written informed consent was obtained from each
participant. For those younger than 18 years, parents also provided
written informed consent.
At pre-intervention, participants were seen on three occasions
for the administration of behavioural questionnaires, neurocogni-
tive tests, the WAIS or WISC intelligence test and EEG measure-
ments, where applicable medication was taken as normal on the
day of assessment. Interventions took place between December
2009 and July 2012. The duration of the intervention period was
approximately 25 weeks. Data collection continued until August
2013. Post-intervention and 1-year follow-up assessments inclu‐
ded behavioural questionnaires and neurocognitive tests for all 60
participants. There were missing data for the D2 Attention and
Concentration Test (two participants), Stroop test (two partici-
pants), TOL (one participant) either because of administrative
problems or because the participant refused to complete the task.
Parent reports (Child Behavior Checklist41 and Autism Spectrum
Quotient42) were not included because of the low response rate
(48%) of the total randomised sample at the follow-up
measurements.
Statistical analysis
All analyses were performed by using SPSS version 19.0. Differences
in group characteristics were analysed with a one-way ANOVA or a
chi-squared test (χ2) with Fisher’s exact correction. Attrition
analyses for behavioural data with smaller sample size than the
total sample size due to missing or incomplete data were performed
by comparing group characteristics and other pre-intervention
primary behavioural measures for the analysed subsample and the
total sample using a one-way ANOVA. Differences were considered
significant at P<0.05 for the group characteristics and the attrition
analyses.
Complete case analysis was performed for participants
who finished all assessments up to 1 year after the intervention
(including neurofeedback training, if applicable), to determine
whether neurofeedback had additional value after completion of
the training. The effect of neurofeedback training was investigated
using a generalised linear model (GLM) with between- and
within-participant factors. To control for multiple tests, effects
were considered significant at P<0.01. This analysis was performed
separately for all outcome measures with treatment group as
between-participants factor and time (i.e. pre-intervention (T1),
post-intervention (T2) and 1-year follow-up (T3)) as within-
particpant factor. The full factorial models were tested. All
behavioural effects were evaluated using multivariate test criteria.
The adjusted difference and 99% confidence interval (99% CI), for
the total sample (NFB+TAU and TAU) are reported.
To determine whether changes over time were associated
with either the co-occurrence of ASD or stimulant medication use,
post hoc analyses were performed to look for three-way interactions
involving diagnostic group (ADHD or ASD with comorbid ADHD)
or stimulant medication use (stimulant-medicated and stimulant-
free) at 1-year follow-up as an additional between-participant
factor.
Intention-to-treat (ITT) analyses were performed to control for
potential outcome bias of individuals who withdrew (n=27) after
randomisation. Separate analyses were performed with ITT ana-
lyses based on imputation with last observation carried forward
(LOCF) and ITT analyses based on imputation with expectation
maximisation (EM). All analyses were performed for the total
group as randomised with the exception of the three excluded
participants (see also flowchart, Fig. 1).
Table 1 Group characteristics
Total NFB+TAU TAU
n=60 n=41 n=19
Age at T1, years: mean (s.d.) 15.95 (3.33) 15.85 (3.34) 16.16 (3.40)
DSM-IV-TR, n (%)
Diagnosis ADHD 38 (63) 26 (63) 12 (63)
Diagnosis ASD+ADHD 22 (37) 15 (37) 7 (37)
Treatment as usual, n (%)
Stimulant medication T1 31 (52) 19 (46) 12 (63)
Stimulant medication T2 29 (48) 17 (41) 12 (63)
Stimulant medication T3 30 (49) 19 (46) 11 (58)
Behavioural interventions,a n (%)
Adolescent T1–T2 22 (37) 13 (32) 9 (47)
Adolescent T2–T3 13 (22) 9 (22) 5 (26)
Adolescent T1–T3 26 (43) 16 (39) 10 (53)
Parent T1–T2 16 (27) 11 (27) 5 (26)
Parent T2–T3 6 (10) 5 (12) 1 (5)
Parent T1–T3 18 (30) 12 (29) 6 (32)
Childhood behaviour, mean (s.d.)
ADHD rating: inattentionb 6.10 (2.46) 5.85 (2.74) 6.63 (1.67)
ADHD rating: hyperactivity/impulsivityb 4.83 (2.80) 4.71 (2.87) 5.11 (2.69)
Intelligence, total IQ: mean (s.d.) 101.12 (11.51) 99.22 (10.61) 105.21 (12.57)
T1, pre-intervention; T2, direct post-intervention; T3, 1-year follow-up; NFB, neurofeedback; TAU, treatment as usual; ADHD, attention-deficit hyperactivity disorder; ASD, autism
spectrum disorder; GAF, Global Assessment of Functioning.
a. Behavioural interventions followed between pre- and post-intervention (T1–T2), between post-intervention and the 1-year follow-up (T2–T3) and between pre-intervention and 1-year
follow-up (T1–T3).





There were no baseline differences for the participants who
completed the study up to 1 year post-treatment in group
characteristics between the NFB+TAU group and the TAU group
(Table 1). There were also no pre-intervention group differences on
behavioural or neurocognitive measures.
There were no significant differences between the treatment
groups in terms of stimulant medication use at pre-intervention or
1-year follow-up. One participant used atomoxetine and stayed
on a stable dose of 60 mg throughout the study. For those who
used immediate or sustained release methylphenidate at 1-year
follow-up (n=29), a slight increase in dose was observed from pre-
intervention (mean 30.83, s.d.=23.39) to 1-year follow-up (mean
37.81, s.d.=18.69; ADT3-T1=8.33, 95% CI 0.07–16.59, F(1,27)=4.28,
P=0.048, ηp
2=0.14). There were no significant interactions between
time and treatment group for dosage, F(1,27)=1.92, P=0.177,
ηp
2=0.07. In addition, those who used medication at 1-year follow-
up (n=30) started stimulant medication at 33 months (s.d.=32.39,
95% CI 20.87–45.06) before 1-year follow-up with no differences
between treatment groups, F(1,28)=0.73, P=0.400.
Attrition analysis
Attrition analysis showed that the participants who dropped out
for motivational or organisational reasons (n=27) did not differ
from the completers group (n=60) in terms of group character-
istics or behavioural measures at pre-intervention. In addition, the
subsamples for the D2 Attention and Concentration Test (n=58)
and the Stroop test (n=57) did not differ from the completers
sample (n=60) in terms of group characteristics, or behavioural
and neurocognitive measures at pre-intervention.
Complete case analyses
Behavioural and neurocognitive outcome measures are sum-
marised in Table 2.
Primary behavioural outcome measures
All behavioural measures showed reductions in reported inatten-
tion and hyperactivity/impulsivity over time, irrespective of treat-
ment group. There were no interactions between treatment group
and time.
Secondary neurocognitive outcome measures
There were no significant interactions between treatment group
and time on the neurocognitive measures. Adolescents showed on
the D2 Attention and Concentration Test an increase in total
processed items and total correctly processed items from pre-
intervention to 1-year follow-up. Similarly, at the 1-year follow-up
adolescents were faster on the TOL with shorter execution times
than at pre-intervention.
Comorbidity of ASD and stimulant medication use
Comorbidity of ASD
Post hoc analysis showed no differences over time between
adolescents with ADHD or combined ASD+ADHD. Furthermore,
there were no interactions between comorbidity of ASD, time and
treatment group.
Stimulant medication use
Stimulant-medicated and stimulant-free adolescents did not differ
over time on the behavioural and cognitive measures. Neither
were there interactions between stimulant medication use, time
and treatment group.
ITT analyses
ITT analyses to control for potential outcome bias due to drop-out
based on LOCF as well as EM showed behavioural and neurocog-
nitive outcomes comparable to the complete case analyses. There
was a decrease of behavioural problems and faster performance
on neurocognitive tasks over time for all adolescents (n=87),
irrespective of treatment group (NFB+TAU or TAU). The trend
(0.01<P<0.05) found in the complete case analysis for the YSR
attention problems subscale (Table 2) did not persist in the ITT
analyses based on LOCF or EM. See supplementary Tables DS1
and DS2.
Discussion
This study investigated the long-term behavioural and neurocog-
nitive effects of supplementing TAU with neurofeedback, using a
multicentre parallel RCT design. Long-term additional effects of
neurofeedback up to 1 year post-intervention have not been
studied before. Overall, the adolescents reported reductions in
ADHD symptoms, irrespective of whether they had received
neurofeedback. Similarly, neurocognitive measures of attention
and processing speed showed improvements between pre-inter-
vention and follow-up indexed by decreased execution time on the
TOL task and increased total processed items on the D2 Attention
and Concentration Test, irrespective of received treatment.
There was no additional benefit from supplementing TAU
with neurofeedback 1 year after treatment. Previously published
results from this RCT showed that adolescents were able to learn
to decrease theta activity within the last five training sessions
compared with the first five training sessions of neurofeedback.43
However, these learning effects did not result in direct additional
value of neurofeedback over TAU on behaviour43 or cognition.30
Our findings are consistent with another RCT16 that found similar
improvements in stimulant-medicated children and children who
had also received neurofeedback. Although Meisel et al16 did not
directly explore the additional value of neurofeedback over TAU,
the naturalistic follow-up is reasonably comparable to the current
study given the fact that 8 of the 12 children who had received
neurofeedback had started stimulant medication treatment and
thus can be considered as a combination group of TAU and
neurofeedback.
In contrast to the current study, one RCT study found long-
term positive results for neurofeedback (n=38) compared with
computerised attention training (n=23), 6 months post-treatment
in stimulant-free children with ADHD.17 In this study, children for
whom stimulant medication was indicated were excluded from the
trial or excluded from the follow-up analysis, potentially excluding
children with more severe ADHD symptoms. Consequently, the
effectiveness of neurofeedback as a treatment for ADHD in this
study cannot be generalised to children with more severe ADHD
symptoms. A recent published RCT18 did overcome this general-
isation problem by including children while standard community
care continued, including stimulant medication use by 47% of the
participants. They found a larger decrease of ADHD problems
from pre-intervention to 6-month follow-up for children that
received neurofeedback in addition to standard community care (n=34)
than children receiving only standard community care (n=36).18
However, significant results were only found on parent reports,
which may be biased in this unmasked study. A meta-analysis into
the effectiveness of non-pharmacological interventions15 indeed
showed that direct behavioural effects of neurofeedback reduced
to non-significant when only probable masked outcomes were
considered. In addition, results of a systematic review44 do not
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follow-up (T3) Adjusted difference
Adjusted
difference [99% CI] at ANOVA
Time (T1–T3)b
ANOVA NFB+TAU & TAU
Over time (T1–T3)cNFB+TAU TAU NFB+TAU TAU NFB+TAU TAU (99% CI) at 1-year 1-year follow-up
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) follow-up (T3–T1)a (T3–T2)a F ηp2 P F ηp2 P
Behaviourd
MINIe df (1,57)
Inattention 5.46 (2.42) 6.32 (2.60) n/a n/a 4.12 (2.56) 4.89 (2.74) −1.38
(−2.26 to −0.50)
n/a 17.53 0.23 0.000 0.01 0.00 0.904
Hyperactivity/
impulsivity
4.17 (2.64) 3.26 (2.13) n/a n/a 2.90 (2.30) 2.74 (2.33) −0.90
(−1.73 to −0.06)
n/a 8.23 0.12 0.006 1.41 0.02 0.241
ADHD-ratingf df (2,57)




15.80 0.36 0.000 0.40 0.01 0.670
Hyperactivity/
impulsivity




5.12 0.15 0.009 1.62 0.05 0.207
YSRg df (2,57)




14.02 0.33 0.000 3.38 0.11 0.041




4.67 0.14 0.013 0.02 0.00 0.974










































56.25 0.67 0.000 1.28 0.04 0.286
DSBi df (2,57)




3.10 0.10 0.053 0.45 0.02 0.640













3.16 0.10 0.050 1.35 0.05 0.268















follow-up (T3) Adjusted difference
Adjusted
difference [99% CI] at ANOVA
Time (T1–T3)b
ANOVA NFB+TAU & TAU
Over time (T1–T3)cNFB+TAU TAU NFB+TAU TAU NFB+TAU TAU (99% CI) at 1-year 1-year follow-up
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) follow-up (T3–T1)a (T3–T2)a F ηp2 P F ηp2 P
TOLk df (2,56)




0.19 0.01 0.825 0.10 0.00 0.906




1.24 0.04 0.296 1.62 0.05 0.208




3.42 0.11 0.040 0.32 0.01 0.727














7.10 0.20 0.002 1.29 0.04 0.283












4.64 0.14 0.014 1.13 0.04 0.329
NFB, neurofeedback; TAU, treatment as usual; MINI, Mini International Neuropsychiatric Interview; ADHD, attention-deficit hyperactivity disorder; YSR, Youth Self Report; D2, D2 Attention and Concentration Test; DSB, digit span backwards; TOL, Tower of London test.
a. Adjusted difference between 1-year follow-up minus pre-intervention are displayed for the total group (NFB+TAU and TAU).
b. Generalised linear model ANOVA with time (pre-intervention (T1) to direct post-intervention (T2) to 1-year follow-up (T3)) as within factor.
c. Generalised linear model ANOVA with time (T1–T2–T3) as within factor and treatment group (NFB+TAU or TAU) as between factor.
d. NFB+TAU (n=41) and TAU (n=19).
e. MINI inattention and hyperactivity/impulsivity were only reported at pre-intervention (T1) and at 1-year follow-up (T3).
f. ADHD rating scale self-reported current symptoms for inattention and hyperactivity/impulsivity.
g. YSR scales: attention problems, externalising problems and total problems.
h. NFB+TAU (n=39) and TAU (n=19).
i. NFB+TAU (n=41) and TAU (n=19).
j. Stroop is measured in seconds, NFB+TAU (n=39) and TAU (n=18).
k. NFB+TAU (n=41) and TAU (n=18).
















support the effectiveness of neurofeedback to enhance neurocog-
nitive functioning.
The effects of comorbid ASD and stimulant medication use and
possible interactions with the effects of the treatment over time
were also explored in the current study. Adolescents with comorbid
ASD did not respond to the interventions differently from
adolescents with ADHD only. Analysis of EEG activity at pre-
intervention revealed that during resting with eyes open and during
task performance adolescents with combined ASD+ADHD showed
significant less theta activity than adolescents with only ADHD.45
Elevated theta and decreased beta activity in ADHD10,11,46 is
associated with decreased vigilance and decreased attention12
respectively. Accordingly, neurofeedback protocols aim to decrease
theta and increase beta and subsequently improve behaviour. Since
adolescents with combined ASD+ADHD display less theta activity
than adolescent with only ADHD, improvements in behaviour by
decreasing theta activity (if possible) using neurofeedback would
probably be less pronounced in adolescents with ASD+ADHD than
in adolescents with only ADHD. However, in the current study
improvements in cognition and behaviour were similar for both
diagnostic groups. Similarly, although stimulant-medicated adoles-
cents with ADHD generally display less theta activity than
stimulant-free adolescents with ADHD,34,47–49 in the current study,
use of stimulant medication did not result in different EEG
patterns45 or intervention outcomes. The absence of specific effects
between stimulant-medicated and stimulant-free adolescents might
be explained by the fact that the majority of the stimulant-
medicated adolescents used stimulant medication for 6 months or
longer at study entry,43 instead of only acute medication effects that
are frequently reported in the literature.
By investigating the long-term effects of neurofeedback as an
additional treatment for adolescents with ADHD with a combina-
tion of behavioural and neurocognitive measures, we aimed to
ensure the ecological validity of the current study. Nevertheless,
this also resulted in several limitations. For example, the target
population consists of a heterogeneous group of male adolescents
with complex problems in a broad age range, and there was variety
in the prescription of stimulant medication. To explore possible
interactions within this heterogeneous population, we performed
post hoc analyses for the presence of comorbid ASD and stimulant
medication use. It should however be noted that splitting up the
treatment groups for these aspects leads to analyses of relatively
small subgroups and a subsequent decrease in power for the
analyses. Accordingly, conclusions with regard to ASD and
stimulant medication should be interpreted cautiously. Further
research, comparing neurofeedback with stimulant medication,
titrated with a stepwise double-masked placebo-controlled proto-
col is essential to see whether neurofeedback is able to be a long-
term alternative for stimulant medication. Another point of
consideration is the absence of masking of the current study.
Masking ensures that expectations about the treatment do not
create a bias in favour of one of the randomised treatment
conditions. However, in the current study, no additional value of
neurofeedback was found. Therefore, it seems unlikely that a
positive expectation bias has influenced the results. Another
limitation is the low response rate for the parent reports at
follow-up, which could therefore not be statistically evaluated.
Most studies into the effectiveness of neurofeedback included
parent reports, sometimes combined with teacher reports on
behaviour. Accordingly, the absence of parent reports and use of
self-reports decrease the ability to directly compare the current
study to former studies. On the other hand, the use of self-reported
behavioural data give new information about whether or not
participants themselves notice improvements in behaviour
over time.
In conclusion, 1 year after treatment the reduction in ADHD
symptoms and improvements in neurocognitive performance
were similar in adolescents who received neurofeedback in
addition to TAU and adolescents receiving TAU alone. These
results do not support the use of theta/SMR neurofeedback as
complementary treatment for TAU to produce enduring improve-
ments in behaviour or neurocognitive functioning in adolescents
with ADHD. Considering the absence of robust additional long-
term effects of neurofeedback, combined with the absence of
specific effects of neurofeedback over sham neurofeedback35,44,50
and the requirement for intensive training (20–40 sessions),10 the
use of theta/SMR neurofeedback as a treatment for adolescents
with ADHD is not supported.
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